These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668 [TBL] [Abstract][Full Text] [Related]
4. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952 [TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654 [TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Alvandi E; Akrami SM; Chiani M; Hedayati M; Nayer BN; Tehrani MR; Nakhjavani M; Pedram M Thyroid; 2011 Apr; 21(4):373-82. PubMed ID: 21309721 [TBL] [Abstract][Full Text] [Related]
7. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Frank-Raue K; Machens A; Scheuba C; Niederle B; Dralle H; Raue F; Clin Endocrinol (Oxf); 2008 Aug; 69(2):259-63. PubMed ID: 18248648 [TBL] [Abstract][Full Text] [Related]
8. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957 [TBL] [Abstract][Full Text] [Related]
9. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma. Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442 [TBL] [Abstract][Full Text] [Related]
10. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075 [TBL] [Abstract][Full Text] [Related]
11. Management of medullary thyroid carcinoma. Jiménez C; Hu MI; Gagel RF Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338 [TBL] [Abstract][Full Text] [Related]
12. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma]. Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799 [TBL] [Abstract][Full Text] [Related]
13. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696 [TBL] [Abstract][Full Text] [Related]
14. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Allen SM; Bodenner D; Suen JY; Richter GT Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888 [TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172 [TBL] [Abstract][Full Text] [Related]
17. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Frank-Raue K; Rondot S; Raue F Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543 [TBL] [Abstract][Full Text] [Related]
19. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. Moura MM; Cavaco BM; Pinto AE; Leite V J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462 [TBL] [Abstract][Full Text] [Related]
20. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report. Menon MM; Simha MR Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]